Paragraf Becomes Diagnostics Systems Co-Developer

The Tachmed deal moves Paragraf up the value chain, because the company is no longer just shipping a sensor chip, it is helping define the full diagnostic workflow, from the graphene transistor inside the cartridge to the connected app and cloud system that turns a signal into a usable health result. That matters because system partners, not part vendors, usually shape the product roadmap, clinical use case, and long term revenue pool in diagnostics.

• Tachmed said the partnership covers co development of next generation tests, integration of Paragraf GFET molecular sensors into TachShield, and scale up of home test cartridge supply. That is a deeper role than selling a standalone sensor to a lab customer.
  1 tachmed
• Paragraf already sells GFETs as research tools, including chips and a discovery kit for molecular sensing experiments. In that model, the customer handles assay design, software, and productization. The Tachmed model instead bundles sensor, cartridge, connected device, software, and APIs into one diagnostic system.
  2 paragraf 4 paragraf
• This also fits Paragraf's broader diagnostics history. Through Cardea, the company inherited earlier work with partners like Biotome and Siemens Healthineers on graphene biosensor platforms for precision immunology and point of care multiomics. Tachmed extends that pattern into home and primary care deployment.
  3 paragraf 5 paragraf 6 paragraf

If this model works, Paragraf can become the graphene sensing layer inside multiple disease specific products, while capturing more of the software, cartridge, and assay economics that sit above the chip. That would make diagnostics a repeatable systems business, not just a semiconductor component line.